P-2196. Utilizing Telemedicine to Engage Rural Patients with Substance Use Disorders in Low Barrier Hepatitis C Treatment
Kristi Hill(Johns Hopkins University), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Tracy Agee(Johns Hopkins University), Mark Sulkowski(Johns Hopkins University), Sherilyn Brinkley, Maria C. Latimer, Patricia Tichnell(Johns Hopkins University)
Cited by 0
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694